Literature DB >> 12721885

The unfinished measles immunization agenda.

Peter Strebel1, Stephen Cochi, Mark Grabowsky, Julian Bilous, Bradley S Hersh, Jean-Marie Okwo-Bele, Edward Hoekstra, Peter Wright, Samuel Katz.   

Abstract

Despite achieving and sustaining global measles vaccination coverage of about 80% over the past decade, worldwide measles remains the fifth leading cause of mortality among children aged <5 years. In May 2002, the United Nations Special Session on Children endorsed the goal of reducing measles deaths by half by 2005. Countries and World Health Organization (WHO) regions that adopted aggressive measles control or elimination strategies have shown excellent results. In 2001, countries in the Americas reported an all time low of 537 confirmed measles cases. Substantial progress in measles control has also been achieved in the WHO Western Pacific Region, in seven southern African countries, and in selected countries in WHO European, Eastern Mediterranean, and Southeast Asian regions. The ongoing measles disease burden and availability of safe and effective measles mortality reduction strategies make a compelling case to complete the unfinished agenda of measles immunization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721885     DOI: 10.1086/368226

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Spatial dynamics of meningococcal meningitis in Niger: observed patterns in comparison with measles.

Authors:  N Bharti; H Broutin; R F Grais; M J Ferrari; A Djibo; A J Tatem; B T Grenfell
Journal:  Epidemiol Infect       Date:  2011-10-05       Impact factor: 2.451

2.  Induction of CD4 T cell proliferation and in vitro Th1-like cytokine responses to measles virus.

Authors:  R C Howe; N Dhiman; I G Ovsyannikova; G A Poland
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

3.  A review of data needed to parameterize a dynamic model of measles in developing countries.

Authors:  Emily K Szusz; Louis P Garrison; Chris T Bauch
Journal:  BMC Res Notes       Date:  2010-03-16

4.  Measles hotspots and epidemiological connectivity.

Authors:  N Bharti; A Djibo; M J Ferrari; R F Grais; A J Tatem; C A McCabe; O N Bjornstad; B T Grenfell
Journal:  Epidemiol Infect       Date:  2010-01-25       Impact factor: 2.451

Review 5.  Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

Authors:  Keri Wellington; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  True Measles Cases Undetected by Reverse Transcription-PCR (RT-PCR): Effect of Genetic Variability on Assay Sensitivity Needs To Be Regularly Surveyed.

Authors:  Julia Dina; Jordane Omnes; Christelle Vauloup-Fellous; Louis Collet; Justine Hamel; Denise Antona; Judith M Hübschen; Myriam Ben Mamou; Astrid Vabret
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

7.  Vaccination coverage and timeliness in three South African areas: a prospective study.

Authors:  Lars T Fadnes; Debra Jackson; Ingunn M S Engebretsen; Wanga Zembe; David Sanders; Halvor Sommerfelt; Thorkild Tylleskär
Journal:  BMC Public Health       Date:  2011-05-27       Impact factor: 3.295

8.  Trends in performance of the national measles case-based surveillance system, Ministry of Health and Child Welfare, Zimbabwe (1999 - 2008).

Authors:  Regis Choto; Addmore Chadambuka; Gerald Shambira; Notion Gombe; Mufuta Tshimanga; Stanley Midzi; Joseph Mberikunashe
Journal:  Pan Afr Med J       Date:  2012-01-11

9.  Effect of thermal environment on the temporal, spatial and seasonal occurrence of measles in Ondo state, Nigeria.

Authors:  Akinyemi Gabriel Omonijo; Andreas Matzarakis; Olusegun Oguntoke; Clement Olabinjo Adeofun
Journal:  Int J Biometeorol       Date:  2011-09-18       Impact factor: 3.738

10.  Modelling the effect of a booster vaccination on disease epidemiology.

Authors:  M E Alexander; S M Moghadas; P Rohani; A R Summers
Journal:  J Math Biol       Date:  2005-11-10       Impact factor: 2.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.